Myron Nevins

Myron Nevins

Auto-generated profile, based on publicly available information

Myron Nevins

Division of Periodontology, Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Journal of Periodontology
Verified
Journal Article
Closed access
PDF file
MNMyron Nevins
Myron Nevins
RKRichard T. Kao
Richard T. Kao
MMMichael K. McGuire
Michael K. McGuire
PMPamela K. McClain
Pamela K. McClain
JHJames E. Hinrichs
James E. Hinrichs
WGWilliam V. Giannobile
William V. Giannobile
Background: Recombinant human platelet‐derived growth factor (rhPDGF) is safe and effective for the treatment of periodontal defects in short‐term studies up to 6 months in duration. We now provide results from a 36‐month extension study of a multicenter, randomized, controlled clinical trial evaluating the effect and long‐term stability of PDGF‐BB treatment in patients with localized severe periodontal osseous defects.Methods: A total of 135 participants were enrolled from six clinical centers for an extension trial. Eighty‐three individuals completed the study at 36 months and were included in the analysis. The study investigated the local application of β‐tricalcium phosphate scaffold matrix with or without two different dose levels of PDGF (0.3 or 1.0 mg/mL PDGF‐BB) in patients possessing one localized periodontal osseous defect. Composite analysis for clinical and radiographic evidence of treatment success was defined as percentage of cases with clinical attachment level (CAL) ≥2.7 mm and linear bone growth (LBG) ≥1.1 mm.Results: The participants exceeding this composite outcome benchmark in the 0.3 mg/mL rhPDGF‐BB group went from 62.2% at 12 months, 75.9% at 24 months, to 87.0% at 36 months compared with 39.5%, 48.3%, and 53.8%, respectively, in the scaffold control group at these same time points (P <0.05). Although there were no significant increases in CAL and LBG at 36 months among all groups, there were continued increases in CAL gain, LBG, and percentage bone fill over time, suggesting overall stability of the regenerative response.Conclusion: PDGF‐BB in a synthetic scaffold matrix promotes long‐term stable clinical and radiographic improvements as measured by composite outcomes for CAL gain and LBG for patients possessing localized periodontal defects (ClinicalTrials.gov no. CT01530126).

1 April 2008
Verified
Journal Article
Closed access
MNMyron Nevins
Myron Nevins
MNMarc L Nevins
Marc L Nevins
MCMarcelo Camelo
Marcelo Camelo
JBJanie Lee Boyesen
Janie Lee Boyesen
DKDavid M. Kim
David M. Kim

1 June 2010
Verified
Journal Article
Closed access
MNMyron Nevins
Myron Nevins
DKDavid M. Kim
David M. Kim
SJSang-Ho Jun
Sang-Ho Jun
KGKevin Guze
Kevin Guze
PSPeter Schupbach
Peter Schupbach
MNMarc L Nevins
Marc L Nevins

1 February 2003
Verified
Journal Article
Closed access
MNMarc L Nevins
Marc L Nevins
MCMarcelo Camelo
Marcelo Camelo
SLSamuel E Lynch
Samuel E Lynch
RSRobert K Schenk
Robert K Schenk
MNMyron Nevins
Myron Nevins

11 October 2023 in Bioengineering
Verified
Journal Article
Open access
PDF file
MNMyron Nevins
Myron Nevins
CCChia-Yu Chen
Chia-Yu Chen
SPStephano Parma-Benfenati
Stephano Parma-Benfenati
DKDavid M. Kim
David M. Kim
Recent technological advancements led to the development of various plasma-based technologies for post-packaging modifications. The purpose of the present preclinical in vivo study was to assess the safety and efficacy of a novel chairside nonthermal gas plasma treatment for enhancing osseointegration of titanium implants. Six male mixed foxhounds underwent extraction of mandibular premolars and first molars, and the sockets healed for 42 days. Canine mandibles were randomized to receive either plasma-treated (test) or non-plasma-treated (control) dental implants. A total of 36 implants were placed in six animals, and they were sacrificed at 2 weeks (two animals), 4 weeks (two animals), and 6 weeks (two animals) after the implant surgery. When the radiographic analysis was performed, the changes in bone level were not statistically significant between the two groups at 2 weeks and 4 weeks. The difference became significant at 6 weeks (p = 0.016), indicating more bone loss from baseline to 6 weeks for the control group. The bone-to-implant contact (BIC) appeared to be higher for the test groups at all time points, and the BIC was significantly higher for the test group at 4 weeks (p = 0.046). In conclusion, this study underscored the potential of nonthermal plasma treatment in enhancing implant osseointegration.

1 May 2013 in International Journal of Periodontics & Restorative Dentistry
Verified
Journal Article
Closed access
MNMyron Nevins
Myron Nevins
MNMarc Nevins
Marc Nevins
LGLuca Gobbato
Luca Gobbato
HLHyo-Jung Lee
Hyo-Jung Lee
CWChin-Wei Wang
Chin-Wei Wang
DKDavid M. Kim
David M. Kim
Myron Nevins, DDS/Marc Nevins, DMD, MMSc/Luca Gobbato, DDS, MS/Hyo-Jung Lee, DDS, PhD/Chin-Wei Wang, DDS/David M. Kim, DDS, DMSc: Interimplant papillae are critical for achieving esthetic implant-supported restorations in the maxillary esthetic zone. Stable papillary anatomy, however, depends upon a stable volume of underlying crestal bone for support. Multiple studies have documented a critical interimplant distance of 3 mm under which crestal bone resorption occurs. This preclinical proofof- principle canine study examines a novel implant-abutment system design, combining platform switching with precisely configured laserablated abutment and implant microgrooves to maintain interimplant crestal bone at interimplant distances of 2 and 4 mm. Results of this initial preclinical study suggest that it is possible through precise implant/ abutment design modifications to place adjacent implants at distances of 2 to 4 mm without inducing subpapillary crestal bone loss. (Int J Periodontics Restorative Dent 2013;33:261?267. doi: 10.11607/prd.1773)